STENTYS: 2019 Financial Calendar
10 Décembre 2018 - 5:45PM
Business Wire
Regulatory News:
STENTYS (Paris:STNT) (FR0010949404 — STNT), French
group specialized in medical technologies for interventional
cardiology, today announced its preliminary financial calendar for
2019.
Event Date * Full-Year 2018 Revenues
Thursday, January 10, 2019 Full-Year 2018 Results
Thursday, March 28, 2019 Q1 2019 Revenues
Thursday, April 11, 2019 Shareholders’ General Meeting
Thursday, May 9, 2019 Q2 2019 Revenues
Thursday, July 11, 2019 Half-Year 2019 Results
Thursday, September 26, 2019 Q3 2019 Revenues
Thursday, October 10, 2019
Financial year end on 31
December
* Subject to modification. Press releases are published after
financial markets close.
About STENTYS
The STENTYS group develops and markets minimally-invasive
cardiovascular solutions for the needs of interventional
cardiology. Its extensive range of innovative products, including
drug-eluting stents, coronary and drug-eluting balloons as well as
cardiovascular accessories, is marketed in over 60 countries.
Thanks to its flagship product, Xposition S, the self-apposing
stent that adapts to vessels with variable diameters and enables
the treatment of complex arterial disorders, and to its portfolio
of balloons and accessories, STENTYS covers all coronary
indications.
Additional information is available at www.stentys.com
STENTYS is listed on Compartment C of Euronext ParisISIN:
FR0010949404 – Ticker: STNT
Forward-looking Statements
This press release contains forward-looking statements about the
Company that are based on numerous assumptions regarding the
Company’s present and future business strategies and the
environment in which it will operate in the future which may not be
accurate. Such forward-looking statements involve known and unknown
risks which may cause the Company’s actual results, performance or
achievements to differ materially from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others,
risks associated with the development and commercialization of the
Company’s products, market acceptance of the Company’s products,
its ability to manage growth, the competitive environment in
relation to its business area and markets, its ability to enforce
and protect its patents and proprietary rights, uncertainties
related to the U.S. FDA approval process, slower than expected
rates of patient recruitment for clinical trials, the outcome of
clinical trials, and other factors, including those described in
the Section 4 “Risk Factors” of the Company’s 2016 Registration
Document (document de référence) filed with the French Autorité des
Marchés Financiers (AMF) on November 29, 2017 under number
D.17-1084.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181210005410/en/
STENTYSAndré LereboursCFOTel.: +33 (0)1 44 53 99
42investor@stentys.com
NewCapInvestor Relations / Strategic CommunicationsDusan
Oresansky / Alexia FaureTel.: +33 (0)1 44 71 94
92stentys@newcap.eu